Improving measures of disease activity in systemic lupus erythematosus

References

• Petri M, Buyon J, Kim M. Classification and definition of major flares in SLE clinical trials. Lupus. 1999;8(8):685–691.
   PubMed Web of Science ®Google Scholar
• Nikpour M, Urowitz MB, Ibañez D, et al. Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. Arthritis Rheum. 2009 Sep;61(9):1152–1158.
   PubMed Web of Science ®Google Scholar
• Strand V, Gladman D, Isenberg D, et al. Endpoints: consensus recommendations from OMERACT IV. outcome measures in rheumatology. Lupus. 2000;9(5):322–327.
   PubMed Web of Science ®Google Scholar
• Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. the committee on prognosis studies in SLE. Arthritis Rheum. 1992 Jun;35(6):630–640.
   PubMed Web of Science ®Google Scholar
• Hawker G, Gabriel S, Bombardier C, et al. A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus. J Rheumatol. 1993 Apr;20(4):657–660.
   PubMed Web of Science ®Google Scholar
• Petri M, Hellmann D, Hochberg M. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol. 1992 Jan;19(1):53–59.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol. 2000 Feb;27(2):377–379.
   PubMed Web of Science ®Google Scholar
• Becker-Merok A, Nossent HC. Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality. J Rheumatol. 2006 Aug;33:1570–1577.
   PubMed Web of Science ®Google Scholar
• Zonana-Nacach A, Yañez P, Jiménez-Balderas FJ, et al. Disease activity, damage and survival in Mexican patients with acute severe systemic lupus erythematosus. Lupus. 2007;16:997–1000.
   PubMed Web of Science ®Google Scholar
• Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med [Internet]. 2005 Dec 15; 353(24)2550–2558.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002 Feb;29(2):288–291.
   PubMed Web of Science ®Google Scholar
• Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research, Bencivelli W, Vitali C, Isenberg DA, et al. III. Development of a computerised clinical chart and its application to the comparison of different indices of dise. Clin Exp Rheumatol. 1992;10(5):549–554.
   PubMedGoogle Scholar
• Hay EM, Bacon PA, Gordon C, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993 Jul;86(7):447–458.
   PubMedGoogle Scholar
• Touma Z, Urowitz MB, Ibañez D, et al. SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. Lupus. 2011 Jan;20(1):67–70.
   PubMed Web of Science ®Google Scholar
• Touma Z, Urowitz MB, Gladman DD. SLEDAI-2K for a 30-day window. Lupus. 2010 Jan;19(1):49–51.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Su J, et al. A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. Rheumatology (Oxford). 2018 Aug;57(8):1370–1376.
   PubMed Web of Science ®Google Scholar
• Bae SC, Koh HK, Chang DK, et al. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus. 2001;10(6):405–409.
   PubMed Web of Science ®Google Scholar
• Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol. 2000 Mar;27(3):664–670.
   PubMed Web of Science ®Google Scholar
• Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research, Vitali C, Bencivelli W, Isenberg DA, et al. II. Identification of the variables indicative of disease activity and their use in the development of an activity s. Clin Exp Rheumatol. 1992;10(5):541–547.
   PubMed Web of Science ®Google Scholar
• Vitali C, Bencivelli W, Mosca M, et al. Development of a clinical chart to compute different disease activity indices for systemic lupus erythematosus. J Rheumatol. 1999 Feb;26(2):498–501.
   PubMed Web of Science ®Google Scholar
• Symmons DP, Coppock JS, Bacon PA, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988 Nov;69(259):927–937.
   PubMedGoogle Scholar
• Liang MH, Socher SA, Larson MG, et al. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 1989 Sep;32(9):1107–1118.
   PubMedGoogle Scholar
• Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol. 1994 Aug;21(8):1468–1471.
   PubMed Web of Science ®Google Scholar
• Brunner HI, Feldman BM, Bombardier C, et al. Sensitivity of the systemic lupus erythematosus disease activity index, british isles lupus assessment group index, and systemic lupus activity measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999 Jul;42(7):1354–1360.
   PubMedGoogle Scholar
• Gordon C, Sutcliffe N, Skan J, et al. Definition and treatment of lupus flares measured by the BILAG index. Rheumatology (Oxford). 2003 Nov;42(11):1372–1379.
   PubMed Web of Science ®Google Scholar
• Stoll T, Stucki G, Malik J, et al. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis. 1996 Oct;55(10):756–760.
   PubMed Web of Science ®Google Scholar
• Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol. 1992 Apr;19(4):608–611.
   PubMed Web of Science ®Google Scholar
• Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep;61(9):1143–1151.
   PubMed Web of Science ®Google Scholar
• Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011 Feb;377(9767):721–731.
   PubMed Web of Science ®Google Scholar
• Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 Jul;44(7):902–906.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibañez D, et al. Systemic lupus erythematosus disease activity index 2000 responder index-50 enhances the ability of SLE responder index to identify responders in clinical trials. J Rheumatol. 2011 Nov;38(11):2395–2399.
   PubMed Web of Science ®Google Scholar
• Yee C-S, Farewell V, Isenberg DA, et al. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity. Arthritis Rheum. 2006 Oct;54(10):3300–3305.
   PubMedGoogle Scholar
• Yee C-S, Farewell V, Isenberg DA, et al. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum. 2007 Dec;56(12):4113–4119.
   PubMedGoogle Scholar
• Carter LM, Gordon C, Yee C-S, et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford). 2022 Jan;61(10):4006–4015.
   PubMed Web of Science ®Google Scholar
• Askanase A, Li X, Pong A, et al. Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments. Lupus Sci Med. 2015;2(1):e000075–e000075.
   PubMedGoogle Scholar
• Abdelhady EI, Rabie M, Hassan RA. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). Clin Rheumatol. 2021 Nov;40(11):4553–4558.
   PubMed Web of Science ®Google Scholar
• Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis. 2019;78:365–371.
   PubMed Web of Science ®Google Scholar
• Chessa E, Piga M, Floris A, et al. Use of Physician Global Assessment (PGA) in Systemic lupus erythematosus: a systematic review of its psychometric properties. medRxiv [Internet]. 2020 Jan 1;[2020 April 14]. 20064683
   Google Scholar
• Uribe AG, Vilá LM, McGwin GJ, et al. The systemic lupus activity measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol. 2004 Oct;31(10):1934–1940.
   PubMed Web of Science ®Google Scholar
• Fatemi A, Raeisi A, Sayedbonakdar Z, et al. Sensitivity analyses of four systemic lupus erythematosus disease activity indices in predicting the treatment changes in consecutive visits: a longitudinal study. Clin Rheumatol. 2018 Apr;37(4):955–962.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011 Jan;38(1):69–78.
   PubMed Web of Science ®Google Scholar
• Furie R, Rovin BH, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020 Sep;383(12):1117–1128.
   PubMed Web of Science ®Google Scholar
• Rovin BH, Teng YKO, Ginzler EM, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (Aurora 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 May;397(10289):2070–2080.
   PubMed Web of Science ®Google Scholar
• Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area And Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol. 2005 Nov;125(5):889–894.
   PubMed Web of Science ®Google Scholar
• Kuhn A, Meuth AM, Bein D, et al. Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus. Br J Dermatol. 2010 Jul;163(1):83–92.
   PubMed Web of Science ®Google Scholar
• Furie RA, Morand EF, Bruce IN, et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol [Internet]. 2019Dec1; 1:e208–19
   PubMedGoogle Scholar
• Morand EF, Furie R, Tanaka Y, et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med. 2020 Jan;382(3):211–221.
   PubMed Web of Science ®Google Scholar
• Werth VP, Fleischmann R, Robern M, et al. Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study. Rheumatology (Oxford). 2022 May;61(6):2413–2423.
   PubMed Web of Science ®Google Scholar
• Furie RA, Hough DR, Gaudy A, et al. Iberdomide in patients with systemic lupus erythematosus: a randomised, double-blind, placebo-controlled, ascending-dose, phase 2a study. Lupus Sci Med. 2022 Feb;9.
   Web of Science ®Google Scholar
• Ceccarelli F, Perricone C, Massaro L, et al. The role of disease activity score 28 in the evaluation of articular involvement in systemic lupus erythematosus. ScientificWorldJournal. 2014;2014:236842.
   PubMedGoogle Scholar
• Zayat AS, Mahmoud K, Md Yusof MY, et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. Rheumatology (Oxford). 2019 Feb;58(2):304–312.
   PubMed Web of Science ®Google Scholar
• Salliot C, Denis A, Dernis E, et al. Ultrasonography and detection of subclinical joints and tendons involvements in Systemic Lupus erythematosus (SLE) patients: a cross-sectional multicenter study. Jt Bone Spine. 2018;85:741–745.
   PubMed Web of Science ®Google Scholar
• The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum [Internet]. 1999 Apr 1;42(4)599–608.
   PubMed Web of Science ®Google Scholar
• Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005 Apr;64(4):620–625.
   PubMed Web of Science ®Google Scholar
• Petri M, Naqibuddin M, Sampedro M, et al. Memantine in systemic lupus erythematosus: a randomized, double-blind placebo-controlled trial. Semin Arthritis Rheum. 2011 Oct;41(2):194–202.
   PubMed Web of Science ®Google Scholar
• Tayer-Shifman OE, Green R, Beaton DE, et al. Validity evidence for the use of automated neuropsychologic assessment metrics as a screening tool for cognitive impairment in systemic lupus erythematosus. Arthritis Care Res (Hoboken) [Internet]. 2020 Dec 1; 72(12)1809–1819.
   PubMed Web of Science ®Google Scholar
• Silvagni E, Chessa E, Bergossi F, et al. Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review. Rheumatology (Oxford). 2021 Dec;61(1):8–23.
   PubMed Web of Science ®Google Scholar
• Ibañez D, Urowitz MB, Gladman DD. Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. J Rheumatol. 2003 Sep;30(9):1977–1982.
   PubMed Web of Science ®Google Scholar
• Ibañez D, Gladman DD, Touma Z, et al. Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time. J Rheumatol. 2011 Jan;38(1):60–63.
   PubMed Web of Science ®Google Scholar
• Petri M, Merrill J, Maciuca R, et al. FRI0293 validation of the revised SELENA flare index in systemic lupus erythematosus. Ann Rheum Dis. 2014 Jan 23;72:A473–4.
   Web of Science ®Google Scholar
• Thanou A, Chakravarty E, James JA, et al. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford) [Internet]. 2014 April 11;53(12):2175–2181.
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Statkute L, et al. Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA [Internet]. 2006 Feb 1; 295(5)527–535.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 Nov;60(11):5379–5389.
   PubMed Web of Science ®Google Scholar
• Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 Jun;77(6):883–889.
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis. 2014 Jan;73(1):183–190.
   PubMed Web of Science ®Google Scholar
• Touma Z, Gladman DD, Ibañez D, et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. J Rheumatol. 2011 Feb;38(2):275–284.
   PubMed Web of Science ®Google Scholar
• Golder V, Kandane-Rathnayake R, Huq M, et al. Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study. Lancet Rheumatol [Internet]. 2019 Oct 1; 1(2)e95–102.
   Google Scholar
• Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis. 2016 Sep;75(9):1615–1621.
   PubMed Web of Science ®Google Scholar
• Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017 Jan;56(1):121–128.
   PubMed Web of Science ®Google Scholar
• Sharma C, Raymond W, Eilertsen G, et al. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2020 Mar;72(3):447–451.
   PubMed Web of Science ®Google Scholar
• Piga M, Floris A, Cappellazzo G, et al. Failure to achieve lupus low disease activity state (LLDAS) six months after diagnosis is associated with early damage accrual in Caucasian patients with systemic lupus erythematosus. Arthritis Res Ther. 2017 Nov;19(1):247.
   PubMedGoogle Scholar
• Kang J-H, Shin M-H, Choi S-E, et al. Comparison of three different definitions of low disease activity in patients with systemic lupus erythematosus and their prognostic utilities. Rheumatology (Oxford). 2021 Feb;60(2):762–766.
   PubMed Web of Science ®Google Scholar
• Morand EF, Trasieva T, Berglind A, et al. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab. Ann Rheum Dis. 2018 May;77(5):706–713.
   PubMed Web of Science ®Google Scholar
• Oon S, Huq M, Golder V, et al. Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus. Ann Rheum Dis. 2019 May;78(5):629–633.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Bertsias G, Doria A, et al. DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med. 2021 Nov 8;8(1):e000538.
   PubMed Web of Science ®Google Scholar
• Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Ann Rheum Dis. 2017 Dec;76(12):2071–2074.
   PubMed Web of Science ®Google Scholar
• Morand EF, Isenberg DA, Wallace DJ, et al. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 Oct;59(10):2930–2938.
   PubMed Web of Science ®Google Scholar
• Abrahamowicz M, Esdaile JM, Ramsey-Goldman R, et al. Development and validation of a novel evidence-based lupus multivariable outcome score for clinical trials. Arthritis Rheumatol (Hoboken, NJ). 2018;70:1450–1458.
   PubMed Web of Science ®Google Scholar
• Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford). 2021 Dec;61:3309–3316.
   Web of Science ®Google Scholar
• Werth VP, Furie RA, Romero-Diaz J, et al. Trial of Anti-BDCA2 antibody litifilimab for cutaneous lupus erythematosus. N Engl J Med [Internet]. 2022 Jul 27; 387:321–331
   PubMed Web of Science ®Google Scholar
• Furie RA, Aroca G, Cascino MD, et al. B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis [Internet]. 2022 Jan 1; 81:100–107
   PubMed Web of Science ®Google Scholar
• Morand EF, Furie RA, Bruce IN, et al. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. Lancet Rheumatol [Internet]. 2022;4:e282–92.
   Google Scholar
• Bruce IN, Furie RA, Morand EF, et al. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis [Internet]. 2022Jul1; 81: 962–969
   PubMed Web of Science ®Google Scholar